We call on the Government to fund vorasidenib for NHS patients with IDH-mutant low-grade glioma, notwithstanding the NICE decision on whether to so or not.

People with this rare brain tumour are often young and trying to live full lives. Vorasidenib could give them more time before harsh treatments, more time with family, more time to hope. It feels wrong to deny that chance when a safe, effective therapy already exists.